LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed its open label trial evaluating 8 mg twice-daily compared to 16 mg once-daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results